Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for details on EVO ICL adoption, new FDA indications, or the cost of expanding Staar Surgical’s Swiss manufacturing line? Those answers live inside the company’s SEC documents—but combing through a 300-page annual report can be daunting. This page gathers every Staar Surgical SEC filing in one place and pairs it with AI-powered explanations so you can focus on the numbers, not the jargon.
Whether you need a Staar Surgical quarterly earnings report 10-Q filing before tomorrow’s call or want to monitor Staar Surgical insider trading Form 4 transactions in real time, our platform surfaces the right document instantly and highlights the sections that matter. Expect:
- Staar Surgical annual report 10-K simplified with key metrics on lens unit growth and geographic revenue mix.
- Form 4 alerts that flag Staar Surgical executive stock transactions Form 4 minutes after they hit EDGAR.
- 8-K material events explained—quality-system audits, regulatory approvals, or distributor agreements—in clear language.
Each filing also comes with concise AI summaries, ratio tables, and plain-English answers to common questions such as “How is R&D capitalised?” or “What does the proxy statement say about executive compensation?” By understanding Staar Surgical SEC documents with AI, you can quickly spot shifts in gross margin, track insider sentiment, and compare quarter-over-quarter lens shipments—without wading through dense legal text. From Staar Surgical proxy statement executive compensation details to Staar Surgical earnings report filing analysis, every document is updated in real time and fully searchable. Complex ophthalmic disclosures, now clear and actionable.
Broadwood Partners, L.P. and related parties reported open-market purchases of STAAR Surgical (STAA) common stock. On 11/19/2025, they purchased 309,132 shares at a weighted average price of
Following these transactions, Broadwood Partners directly beneficially owned 15,019,491 shares of common stock, and 25,900 shares were directly owned by Neal C. Bradsher. The reporting persons include Broadwood Partners, L.P., Broadwood Capital, Inc. and Neal C. Bradsher, who is identified as a director and 10% owner. The parties state that each disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest.
Broadwood Partners and its affiliates filed additional proxy materials for STAAR Surgical’s contested sale to Alcon. The group updated its LetSTAARShine.com website to include a November 18, 2025 Investing.com article describing new board-level dissent over STAAR’s amended $28-per-share merger agreement with Alcon. The article notes that one director opposed the revised terms, while five directors approved them after efforts to obtain a higher price did not succeed and a tail fee provision was removed.
These materials relate to a special stockholder meeting currently scheduled for October 23, 2025 to consider the transaction, as well as a separate special meeting Broadwood intends to call to remove certain directors. The exhibits and website highlight prior public opposition to the deal, recommendations by multiple proxy advisors to vote against it, and Broadwood’s campaign criticizing the proposed sale and supporting board changes.
STAAR Surgical (STAA) reported an insider equity change on Form 4. On 11/12/2025, Director Wei Jiang acquired 20,967 shares of common stock at $0 per share, following the vesting and settlement of restricted stock units (Transaction Code: M).
After this transaction, Jiang beneficially owns 45,477 shares, held directly. The RSUs were granted on May 12, 2025 and vest in three equal tranches of 20,967 shares each: on August 12, 2025, November 12, 2025, and January 12, 2026.
According to prior disclosures, Jiang is serving through fiscal 2025 as a special strategic advisor to the company’s Asia Pacific business in the temporary role of Chief of APAC Strategy; this transaction reflects vesting tied to that service.
STAAR Surgical Company entered into Amendment No. 1 to its merger agreement with Alcon Research, LLC and Rascasse Merger Sub, Inc., adding a go-shop window and adjusting termination terms.
The amendment permits the Company to solicit, facilitate and encourage Acquisition Proposals, including by sharing non-public information, from
Separately, the special meeting to vote on the merger has been postponed to
STAAR Surgical (STAA): Activist DFAN14A update and governance push. Broadwood and affiliates updated their campaign website and filed materials that incorporate a letter from Yunqi Capital, a 5.1% shareholder. Yunqi cites STAAR’s third-quarter metrics to argue against the proposed $28-per-share sale to Alcon.
According to Yunqi’s letter, reported operating expenses were $59.4 million; excluding $5.9 million of merger-related costs, the underlying run rate was $53.5 million, which it says annualizes to $214 million versus prior guidance of $225 million. Yunqi also notes cash, cash equivalents, and investments of $192.7 million, up from $189.9 million at the prior quarter-end. The dissident group urges shareholders to use the GREEN proxy card for the special meeting scheduled for October 23, 2025, and contends that recent performance supports terminating the Alcon transaction.
Yunqi Capital filed a Notice of Exempt Solicitation concerning STAAR Surgical (STAA) and the proposed sale to Alcon. In an attached letter, the 5.1% shareholder urges the Board to terminate the $28 per share transaction, citing what it describes as strong third‑quarter performance and improving fundamentals.
Yunqi points to reported operating expenses of $59.4 million, including $5.9 million of merger‑related costs, implying an underlying run rate of $53.5 million that it says annualizes to $214 million versus prior guidance of $225 million. It also notes cash, cash equivalents, and investments of $192.7 million, up from $189.9 million. The firm challenges Alcon’s presentation of China market data, asks STAAR’s Board to communicate directly with shareholders, and proposes adding a director with meaningful ownership. Yunqi states that 72% of outstanding shares had voted against the deal as of the originally scheduled October 23 special meeting.
STAAR Surgical Company (STAA) filed its Q3 report and detailed a pending merger with Alcon. Under the agreement, each share will be converted into $28.00 in cash at closing, subject to stockholder approval and other conditions. The HSR waiting period has expired, and the special meeting to vote on the merger is scheduled for December 3, 2025.
Q3 results: Net sales were $94.7 million versus $88.6 million a year ago, with gross margin at 82.2%. Net income was $8.9 million. Year‑to‑date net sales were $181.6 million versus $265.0 million, and the company reported a net loss of $62.1 million, reflecting $27.9 million in restructuring, impairment and related charges and $5.9 million in merger-related costs.
China dynamics remain central. Q3 China sales were $55.8 million, including $25.9 million recognized from a December 2024 shipment collected in Q3 at 100% gross margin. The company shifted to consignment arrangements in China and increased consigned inventory to manage tariff risk. Cash and equivalents were $176.2 million, with year‑to‑date operating cash flow of $(30.3) million. The board authorized a $30 million buyback; $23.5 million remained available as of quarter end.
STAAR Surgical Company furnished a press release reporting its financial results for the quarter ended September 26, 2025. The release is provided as Exhibit 99.1 to this report.
The information furnished under Item 2.02 is expressly stated as not being “filed” for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into Securities Act or Exchange Act filings.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
